22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Beginning September 1, 2019, the IRS is expanding its retirement plan determination letter program t...
Read More >
The North Carolina Supreme Court recently issued a decision in Crescent University City Venture, LLC...
Read More >
On September 18, California Governor Gavin Newsom signed Assembly Bill 5 (AB 5), which adds Section ...
Read More >
The Tennessee Air Pollution Control Board (“TAPCB”) issued an October 24th Technical Secretary’s ...
Read More >
In Pennsylvania, the Workers’ Compensation Act is considered a remedial act that is to be liberally...
Read More >
Key Points - • Tight labor markets are leading courts and legislatures to closely scrutinize nonc...
Read More >